Comparative Pharmacology
Head-to-head clinical analysis: FOLLISTIM AQ versus REPRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLLISTIM AQ versus REPRONEX.
FOLLISTIM AQ vs REPRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased cAMP production.
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing cAMP and promoting follicular development and estrogen synthesis.
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
None Documented
None Documented
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Category C
Category C
Gonadotropin
Gonadotropin